But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
ApexOnco Front Page
Recent articles
2026’s first big oncology buyout is here.
But Repare and Black Diamond still have rebuilding to do.
After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.
After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.
ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.
With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.
Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.